WO2010030947A1 - System and method for producing t cells - Google Patents
System and method for producing t cells Download PDFInfo
- Publication number
- WO2010030947A1 WO2010030947A1 PCT/US2009/056739 US2009056739W WO2010030947A1 WO 2010030947 A1 WO2010030947 A1 WO 2010030947A1 US 2009056739 W US2009056739 W US 2009056739W WO 2010030947 A1 WO2010030947 A1 WO 2010030947A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- human
- lmdll
- hscs
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 146
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- 108010002586 Interleukin-7 Proteins 0.000 claims abstract description 54
- 238000000034 method Methods 0.000 claims abstract description 36
- 210000002536 stromal cell Anatomy 0.000 claims abstract description 20
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 18
- 210000000130 stem cell Anatomy 0.000 claims abstract description 7
- 210000004027 cell Anatomy 0.000 claims description 67
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 210000001185 bone marrow Anatomy 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 21
- 230000001605 fetal effect Effects 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 11
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 7
- 238000011161 development Methods 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000013603 viral vector Substances 0.000 claims description 3
- 241001529936 Murinae Species 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 2
- 241000700159 Rattus Species 0.000 claims 2
- 241000700199 Cavia porcellus Species 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 102000000704 Interleukin-7 Human genes 0.000 abstract description 46
- 229940100994 interleukin-7 Drugs 0.000 abstract description 45
- 230000011712 cell development Effects 0.000 abstract description 19
- 230000001976 improved effect Effects 0.000 abstract description 5
- 108700014844 flt3 ligand Proteins 0.000 abstract description 3
- 230000003394 haemopoietic effect Effects 0.000 abstract description 3
- 239000002243 precursor Substances 0.000 abstract description 3
- 210000002865 immune cell Anatomy 0.000 abstract description 2
- 210000004970 cd4 cell Anatomy 0.000 abstract 1
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 50
- 238000000338 in vitro Methods 0.000 description 31
- 108091008874 T cell receptors Proteins 0.000 description 24
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 24
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 24
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 19
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 19
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 19
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 19
- 230000004069 differentiation Effects 0.000 description 17
- 230000011664 signaling Effects 0.000 description 16
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 13
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 12
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 11
- 230000024245 cell differentiation Effects 0.000 description 10
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 9
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 8
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 8
- 230000035800 maturation Effects 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 210000004700 fetal blood Anatomy 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000007704 transition Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 5
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 4
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 description 3
- 101100499365 Mus musculus Dlk1 gene Proteins 0.000 description 3
- 101100499378 Mus musculus Dll3 gene Proteins 0.000 description 3
- 108010070047 Notch Receptors Proteins 0.000 description 3
- 102000005650 Notch Receptors Human genes 0.000 description 3
- 102100027654 Transcription factor PU.1 Human genes 0.000 description 3
- 238000011319 anticancer therapy Methods 0.000 description 3
- 230000005975 antitumor immune response Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 210000003317 double-positive, alpha-beta immature T lymphocyte Anatomy 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 210000003162 effector t lymphocyte Anatomy 0.000 description 3
- 102000052622 human IL7 Human genes 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000010212 intracellular staining Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 108010008929 proto-oncogene protein Spi-1 Proteins 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 101000932480 Homo sapiens Fms-related tyrosine kinase 3 ligand Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000011748 cell maturation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 238000012758 nuclear staining Methods 0.000 description 2
- 101150083745 preT gene Proteins 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 206010055008 Gastric sarcoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 102000009875 Ki-67 Antigen Human genes 0.000 description 1
- 108010020437 Ki-67 Antigen Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102000004857 Lymphoid enhancer-binding factor 1 Human genes 0.000 description 1
- 108090001093 Lymphoid enhancer-binding factor 1 Proteins 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 102000009389 Prostaglandin D receptors Human genes 0.000 description 1
- 108050000258 Prostaglandin D receptors Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 108091008778 RORγ2 Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 230000024806 T cell lineage commitment Effects 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 239000012163 TRI reagent Substances 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000011293 immunotherapeutic strategy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 102000004114 interleukin 20 Human genes 0.000 description 1
- 108090000681 interleukin 20 Proteins 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000002037 lung adenoma Diseases 0.000 description 1
- -1 mDLl Proteins 0.000 description 1
- 210000005001 male reproductive tract Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- 208000025440 neoplasm of neck Diseases 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1394—Bone marrow stromal cells; whole marrow
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
Definitions
- T cells play an important role in the establishment of the mammalian immune system.
- the immune system often fails to function properly in patients suffering from chronic infections or cancer (1).
- Large-scale production of T cells with the aim for the treatment of infections and cancer has been of continuous interest.
- Autologous transfer of in vitro expanded antigen-specific lymphocytes is challenged by limited sources of healthy and functional T cells (2).
- Adoptive transfer of allogenic antigen specific effector T cells is limited by availability of such reactive T cells and faces the problem of graft-versus-host disease (GVHD) (3).
- GVHD graft-versus-host disease
- producing large number of antigen specific T cells from adult human bone marrow (BM) derived CD34 hematopoietic precursor/stem cells (HPC) in vitro could help overcome some of the limitations described above.
- Previously established in vitro culture systems for producing human T lymphocytes such as thymus organ cultures and three-dimensional matrices of epithelial cells are labor intensive and difficult to manipulate (4-6). These in vitro culture systems have demonstrated early T cell differentiation from embryonic stem cells of mouse and human origins (7, 8). Recently, a simpler T cell development culture system has been reported that employs mouse fetal stromal cells engineered to express the Notch ligand Delta-like 1 (OP9-DL1), which provides a uniform two- dimensional environment to the differentiating thymocytes (9). OP9-DL1 culture system has been reported to support differentiation of progenitors isolated from murine fetal liver (10), adult bone marrow (BM) (11, 12), and human umbilical cord blood and pediatric BM (13, 14).
- BM adult bone marrow
- BM human umbilical cord blood and pediatric BM
- the present addresses at least three limitations of previously utilized in vitro adult human T cell development systems: the limited expansion of preT cells, the inefficient differentiation to double positive (DP) stage and the lack of positive selection and lineage commitment.
- the inventors have developed an improved system using engineered stromal cells expressing DLl, Flt3-L and/or IL-7, which can enhance preT cell expansion from CD34 HPC.
- the inventors have discovered that continuous IL-7 signaling impairs further differentiation of immature single positive (ISP) thymocytes into DP thymocytes, thus rendering the developing lymphocytes functionally immature.
- ISP immature single positive
- TCR TCR signals.
- CD4 T cells are functionally mature.
- the advent of a simple in vitro culture system for the generation of functional CD4 T cells from adult human HPC enables a number of translational immunotherapeutic strategies.
- FIG. 1 Lentiviral vector-modified mouse fetal stromal cell lines.
- A Lentiviral vector constructs.
- B ELISA analysis of IL-7 secretion by LmDLl and LmDLFL7 cells.
- C Flow cytometry analysis of surface expression of mouse delta like- 1 (DLl).
- D Flow cytometry analysis of Flt3L expression of lentiviral vector-modified stromal cell line LmDLl-FL and LmDLl-FL7.
- FIG. 1 Lentiviral vector-modified LmDLl-FL7 stromal cells support increased expansion of early T lymphocytes
- A Kinetics of T cell development of adult BM CD34 + HPC cultured on LmDLl supplemented with IL-7 and Flt3L, or on LmDLl-FL7. The developing HPC were sampled from the cocultures on different days as indicated, stained with anti-CD4 and anti-CD8 antibodies, and analyzed with flow cytometry.
- B CD3 and TCR ⁇ expression kinetics of adult BM CD34 + HPC cultured on LmDLl supplemented with IL-7 and Flt3L, or on LmDLl-FL7.
- C Proliferation curve of differentiating T cells on LmDLl supplemented with IL- 7 and Flt3L, or on LmDLl-FL7.
- D Flow cytometry analysis of T cell maturation markers and nuclear Ki67 after two weeks of anti-CD3/CD28 stimulation from the day 42 coculture. PBMCs (non-stimulated) were used as a control.
- FIG. 3 Mature CD4 but not CD8 T cell development from the improved in vitro culture system
- A The experimental design. Growth curve for adult BM CD34 + HPC were cultured on LmDLl-FL7 for 24 days and then transferred to LmDLl-FL culture.
- B Flow cytometry analysis of expression kinetics of CD8, CD4, CD3 and TCR ⁇ .
- C Adult BM CD34 + HPC were cultured on LmDLl-FL7 for 24 days and then transferred to LmDLl-FL culture. On day 42, the cells were stimulated and cultured for 14 days before further analysis. Flow cytometry analysis of maturation markers and nuclear Ki67 was performed. PBMCs stimulated under the same condition as above, were used as a control.
- FIG. 4 In vitro derived CD4 T cells are functional with a restricted V ⁇ repertoire
- A T cells stimulated for two weeks were re-stimulated with PMA and ionomycin for 5-6 hours, and stained with antibodies detecting immune effector cytokines and proteins. After removal of IL-7, the T lymphocytes derived from two independent donor BM CD34 + HPC in the LmDLl -FL 7/L- mDLl-FL cocultures were capable of producing IFN- ⁇ , IL-4, and IL- 17, expressed FoxP3 as well as upregulated CD25. Normal PBMC and a primary single cell-derived CD4 T cell clone were included as controls.
- B The V ⁇ repertoire of in vitro derived T lymphocytes from three different adult bone marrow CD34 + HPC donors appeared to be narrow and skewed as compared with a control adult PBMC.
- FIG. 5 The improved in vitro T cell development system is capable of generating mature CD4 T cells from adult human HPC.
- the top diagram illustrated the lack of functional T cell development from the DLl, Flt3L and IL-7 T cell development coculture system.
- the bottom diagram shows that with lentiviral vector-engineered coexpression of DLl, Flt3L and IL-7, plus the intermittent removal of IL-7, increased amount of mature and functional CD4 T cells are generated.
- FIG. 3 Flow cytometric analysis shows that T cell precursors (cultured on OP9FL7 day 42) express high levels of HLA class I and low level of HLA DR DQ DP as compared to stimulated PBMC control.
- (Sl)CD3e analysis shows that the CD8 cells do express CD3e chain of the T cell receptor complex similar to the controls, they low level of GAT A3 a CD4 lineage marker, and they express PU.1 suggesting arrest in immature stage of differentiation.
- HSCs bone marrow-derived hematopoietic stem cells
- OP9-DL1 Delta- like 1
- the invention pertains to a viral vector- modified culture system that can support differentiation of adult human CD34+ HSC to fully mature CD4 T lymphocytes in vitro.
- the engineered stromal cell line expressing DLl, interleukin-7 (IL-7), and FMS-like tyrosine kinase 3 ligand (FL) supports expansion of early differentiated T cells.
- the continuous IL-7 signaling led to differentiation arrest during immature single positive (ISP) CD8 stage.
- ISP immature single positive
- the inventors solved this problem by a combination approach through temporary termination of IL-7 receptor signaling and activation of CD3/CD28 signaling pathway. This modification resulted in the production of mature CD4 T cells that were able to produce effector cytokines including IFN- ⁇ and TNF- ⁇ upon stimulation.
- the invention pertains to a culture system that can support differentiation of adult human CD34+ hematopoietic stem cells (HSCs) to fully mature CD4 T lymphocytes in vitro.
- HSCs hematopoietic stem cells
- the invention pertains to culturing HSCs in the presence of IL-7 and terminating the subjecting of the cells to IL-7 at a certain window of time over the course of development.
- HSCs are co-cultured with cells, such as OP-9 stromal cells, expressing IL-7, mDLl, and Flt3L (typically by transfection with a viral vector, such as lentivirus) for a period of between 14-24 days. At a time between 14-30 days, the HSCs are no longer subjected to IL-7. The HSCs are later subjected to TCR stimulation. The HSCs develop into fully mature and functional CD4 T cells.
- the presently disclosed subject matter also provides methods for inducing an anti-tumor immune response in a subject.
- the methods comprise administering to the subject a composition comprising a plurality of T cells and one or more pharmaceutically acceptable carriers or excipients.
- the anti-tumor immune response is sufficient to (a) prevent occurrence of a tumor in the subject; (b) delay occurrence of a tumor in the subject; (c) reduce a rate at which a tumor develops in the subject; (d) prevent recurrence of a tumor in the subject; (e) suppress growth of a tumor in a subject; or (f) combinations thereof.
- the anti-tumor immune response comprises a cytotoxic T cell response against an antigen present in or on a cell of the tumor.
- the cytotoxic T cell response is mediated by CD8+ T cells.
- compositions and methods can also be employed as part of a multi-component anti-tumor and/or anti-cancer treatment modality.
- the presently disclosed methods further comprise providing to the subject an additional anti-cancer therapy selected from the group consisting of radiation, chemotherapy, surgical resection, immunotherapy, and combinations thereof.
- the additional anti-cancer therapy is provided to the subject at a time prior to, concurrent with, subsequent to, or combinations thereof, the administering step.
- the additional anti-cancer therapy is provided prior to the administering step and the composition is administered as an adjuvant therapy.
- the cancer is selected from the group consisting of bladder carcinoma, breast carcinoma, cervical carcinoma, cholangiocarcinoma, colorectal carcinoma, gastric sarcoma, glioma, lung carcinoma, lymphoma, melanoma, multiple myeloma, osteosarcoma, ovarian carcinoma, pancreatic carcinoma, prostate carcinoma, stomach carcinoma, a head tumor, a neck tumor, and a solid tumor.
- the cancer comprises a lung carcinoma.
- compositions and methods can be employed for prevention and/or treatment of a tumor and/or a cancer in any subject.
- the subject is a mammal.
- the mammal is a human.
- a can refer to one or more cells.
- another can refer to at least a second or more.
- the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”), or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
- treatment effective amount As used herein, the phrases “treatment effective amount”, “therapeutically effective amount”, “treatment amount”, and “effective amount” are used interchangeably and refer to an amount of a composition (e.g., a plurality of ES cells and/or other pluripotent cells in a pharmaceutically acceptable carrier or excipient) sufficient to produce a measurable response (e.g., a biologically or clinically relevant response in a subject being treated).
- a compositions e.g., a plurality of ES cells and/or other pluripotent cells in a pharmaceutically acceptable carrier or excipient
- a measurable response e.g., a biologically or clinically relevant response in a subject being treated.
- actual dosage levels of CD4 T cells in the compositions of the presently disclosed subject matter can be varied so as to administer a sufficient number of CD4 T cells to achieve the desired immune response for a particular subject.
- the selected dosage level will depend upon several factors including, but not limited to the route of administration, combination with other drugs or treatments
- IL-7 means a known IL-7 molecule or a polypeptide having at least 95, 96, 97, or 98 percent identity with IL-7.
- IL-7 sequences of several different species are well known in the art. Examples of genbank accession nos include AAI10554, BCl 10553, AAH47698 and BC047698. Percent identity is determined according to conventional techniques and computer programs. For example, percent identity between two sequences, when optimally aligned such as by the programs GAP or BESTFIT (peptides) using default gap weights, or as measured by computer algorithms BLASTX or BLASTP, share the specified identity.
- residue positions which are not identical differ by conservative amino acid substitutions. For example, the substitution of amino acids having similar chemical properties such as charge or polarity are not likely to effect the properties of a protein. Non-limiting examples include glutamine for asparagine or glutamic acid for aspartic acid.
- cancer and “tumor” are used interchangeably herein and can refer to both primary and metastasized solid tumors and carcinomas of any tissue in a subject, including but not limited to breast; colon; rectum; lung; oropharynx; hypopharynx; esophagus; stomach; pancreas; liver; gallbladder; bile ducts; small intestine; urinary tract including kidney, bladder, and urothelium; female genital tract including cervix, uterus, ovaries (e.g., choriocarcinoma and gestational trophoblastic disease); male genital tract including prostate, seminal vesicles, testes and germ cell tumors; endocrine glands including thyroid, adrenal, and pituitary; skin (e.g., hemangiomas and melanomas), bone or soft tissues; blood vessels (e.g., Kaposi's sarcoma); brain, nerves, eyes, and meninge
- cancer and tumor also encompass solid tumors arising from hematopoietic malignancies such as leukemias, including chloromas, plasmacytomas, plaques and tumors of mycosis fungoides and cutaneous T-cell lymphoma/leukemia, and lymphomas including both Hodgkin's and non-Hodgkin's lymphomas.
- leukemias including chloromas, plasmacytomas, plaques and tumors of mycosis fungoides and cutaneous T-cell lymphoma/leukemia, and lymphomas including both Hodgkin's and non-Hodgkin's lymphomas.
- the terms “cancer and “tumor” are also intended to refer to multicellular tumors as well as individual neoplastic or pre-neoplastic cells.
- a tumor is an adenoma and/or an adenocarcinoma, in some embodiments a lung adenoma and/or adenocarcinoma.
- compositions of the presently disclosed subject matter comprise in some embodiments a pharmaceutically acceptable carrier. Any suitable formulation can be used to prepare the disclosed compositions for administration to a subject.
- the pharmaceutically acceptable carrier is pharmaceutically acceptable for use in a human.
- suitable formulations can include aqueous and non-aqueous sterile injection solutions which can contain anti-oxidants, buffers, bacteriostats, bactericidal antibiotics and solutes which render the formulation isotonic with the bodily fluids of the intended recipient; and aqueous and non-aqueous sterile suspensions which can include suspending agents and thickening agents.
- the formulations can be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and can be stored in a frozen or freeze-dried (lyophilized) condition requiring only the addition of sterile liquid carrier, for example water for injections, immediately prior to use.
- Some exemplary ingredients are SDS, in some embodiments in the range of 0.1 to 10 mg/ml, in some embodiments about 2.0 mg/ml; and/or mannitol or another sugar, in some embodiments in the range of 10 to 100 mg/ml and in some embodiments about 30 mg/ml; and/or phosphate-buffered saline (PBS).
- SDS in some embodiments in the range of 0.1 to 10 mg/ml, in some embodiments about 2.0 mg/ml
- mannitol or another sugar in some embodiments in the range of 10 to 100 mg/ml and in some embodiments about 30 mg/ml
- PBS phosphate-buffered saline
- formulations of the presently disclosed subject matter can include other agents conventional in the art having regard to the type of formulation in question.
- sterile pyrogen-free aqueous and non-aqueous solutions can be used.
- a composition of the presently disclosed subject matter can be administered to a subject in need thereof in any manner that would be expected to generate and enhance an immune response in the subject.
- Suitable methods for administration of a composition of the presently disclosed subject matter include, but are not limited to, intravenous (i.v.), intraperitoneal (i.p.), subcutaneous (s.c), subdermal (s.d.), intramuscular (i.m.), and/or intratumoral injection, and inhalation.
- the presently disclosed subject matter methods comprise administering a therapeutically effective dose of a composition of the presently disclosed subject matter to a subject in need thereof.
- an "effective amount” is an amount of the composition sufficient to produce a measurable response (e.g., enhanced cytolytic and/or cytotoxic response in a subject being treated).
- Example 1 Increased expansion of early T lymphocytes from adult human CD34 + progenitors in a simplified lentiviral vector-modified stromal culture system
- a lentiviral vector-modified mouse fetal stromal cell line (LmDLl) expressing mouse delta-like 1 ligand (DLl) can support early T cell differentiation of human CD34 + HPC from cord blood, fetal thymus, fetal liver and adult bone marrow (16).
- LmDLl mouse fetal stromal cell line
- DLl mouse delta-like 1 ligand
- the secretion of IL-7 by LmDLl-FL7 was measured via ELISA to be in the range of 10-14 ng/mL after 48 hours of culture (Fig.1 B).
- the surface DLl expression on all three lentiviral vector-transduced cell lines (LmDLl, LmDLl-FL and LmDLl-FL7) was substantially higher than that of the endogenous levels on OP9 as shown by flow cytometry (Fig. 1 C).
- High surface expression of Flt3L was also illustrated on LmDLl-FL and LmDLl-FL7 cell lines using anti-Flt3-L antibody (Fig. 1 D).
- T cell development was demonstrated using highly purified (>97%) adult human CD34 + BM cells cultured on LmDLl cells supplemented with recombinant human IL-7 and Flt3-L, or on LmDLl-FL7 cells without any of the growth factor supplements (Fig. 2).
- the LmDLl-FL7 culture exhibited a T cell development course similar to that of the LmDLl culture with slightly higher level of CD8 expression (Fig. 2 A).
- the CD3 and TCR ⁇ expression also differed slightly between the two culture systems (Fig. 2 B). Both systems supported development of adult BM CD34 + cells into CD3TCR ⁇ ⁇ SP CD8 + T cells over the course of 50 to 60 days (Fig. 2).
- LmDLl-FL7 cell line supported increased T cell precursor expansion without altering the T cell differentiation potential.
- IL-7 can be transformed cells to express IL- 7
- other means of transforming cells to express IL- 7 such as, but not limited to, other viral vectors such as but not limited to Adenoviruses, retroviruses or AAV viruses, or naked DNA.
- cell types other than fetal stromal cells can be engineered to express IL-7 for co-culturing purposes.
- IL-7 can be subjected to a target cell type by manually providing to culturing media.
- Example 2 LmDLl-FL7 cell line does not support differentiation of BM CD34 HPC into fully mature T cells
- T cells The transition of differentiating T cells from double negative (DN) to DP stage and CD4 and CD8 lineages requires Notch signaling as well as pre-TCR signaling (22, 23).
- the DP T cells depend exclusively on signals downstream of TCR for survival; at this stage they become unresponsive to cytokine induced survival signals (24, 25).
- cytokine induced survival signals 24, 25.
- Fig. 2 C We observed that the T cell precursors expressed CD3 but died after about 40 days in the IL-7, Flt3L and Notch signaling coculture.
- Fig. 2 C To see if these developing T cells can become mature SP T cells, we provided these T cells with TCR signals by using anti-CD3/anti-CD28 microbeads on day 42 (Fig 2 D). Following the CD3/CD28 stimulation, the cells expressed low levels of CD8 on the surface.
- Example 3 Increased differentiation from pre-T to DP T cells after IL-7 removal
- T cell lineage commitment requires cytokine and co-receptor signals (24).
- cytokine and co-receptor signals 24.
- the IL-7-deprived DP T cells will undergo lineage commitment when given a TCR signal.
- the CD3 and TCR ⁇ co-expression was detected between day 30-42 (donor variation)
- the T cell proliferated as illustrated by Ki67 nuclear staining (Fig. 3 C).
- the T cells differentiated beyond ISP stage as demonstrated by the detection of T cell differentiation and maturation marker including CD3, CD28, and TCR ⁇ but not CDIa (Fig. 3 C, in comparison with similarly stimulated PBMCs).
- IL-7 prevents further T cell differentiation beyond ISP stage and impairs functional maturation of developing adult human T cells.
- these in vitro derived mature T cells were mostly CD4 T cells.
- the removal of IL-7 may bias cell differentiation toward intermediate CD4 + T cells as IL-7 signals are required for the development of CD8 + T cells.
- Subsequent TCR signaling could promote the commitment of intermediate CD4 + CD8 " thymocytes into CD4 + T cells, as prolonged TCR signaling (or higher intensity and long duration) can block co-receptor reversal to CD8 + SP (20, 32).
- in vitro derived CD4 + T cells could display effector T cell functions.
- the in vitro derived CD4 + T lymphocytes as illustrated from two different donors, were able to secrete IFN- ⁇ , IL- 17 and IL-4, and expressed surface CD25 and low levels of intracellular FoxP3 comparable to that of the control PBMC-derived CD4 T cells or a purified primary CD4 T cell clone (Fig.
- V ⁇ repertoire analysis was performed for 23 V ⁇ families using IOTest® Beta Mark TCR V ⁇ Repertoire Kit. The day 42 T cells that expanded into CD4 + SP T cells, were stained with the IOTest® panel of Abs.
- the in vitro derived CD4 + T cells displayed a narrow V ⁇ usage skewed towards particular V ⁇ families (Fig. 4 B). For examples, donor 1 displayed a moderately skewed (>10%) usage of Vb5.1, Vb7.1, Vb 13.1 and Vb 18; donor 2 displayed a skewed usage of Vb2 (15%) and Vb5.2 (29%); donor 3 displayed a highly skewed usage of Vb7.2 (29%) and Vb4 (44%). It appeared that the V ⁇ repertoires of the in vitro derived T lymphocytes were more restricted than those of normal adult PBMCs.
- the OP9-DL1 culture system supports development of early T cells from cord blood and fetal liver HPC, yet has not been shown to generate mature T cells from adult human HPC (8-10, 13, 34). Accumulated studies have revealed that the OP9-DL1 system only supports early T cell differentiation to double positive (DP) stage and detailed characterization and functional analysis of these T cells beyond the DP stage have been lacking (10, 13). Although the OP9-DL1 culture system has greatly facilitated human T cell development studies, it remains difficult to produce large number of mature T cells from adult human HPCs in vitro (35). Here the inventors report a modified version of stromal culture system, LmDLl-FL7, which supports increased early T cell expansion from adult CD34 + HPC without the needs for exogenous cytokines.
- the LmDLl-FL7 cell line alone does not support full T cell development from adult human CD34 + HPC; rather, the differentiating T cells are arrested at immature single positive (ISP) CD8 T cell stage. This problem is resolved by further modifications of the coculture conditions during DN to DP and SP T cell development stage as summarized in Fig. 5.
- IL-7R signaling can inhibit expression of transcriptional factors such as transcription factor- 1 (TCF-I), lymphoid enhancer- binding factor 1 (LEFl), and the orphan hormone receptor ROR ⁇ t, critical for ISP to DP transition in mice (28).
- TCF-I transcription factor- 1
- LEFl lymphoid enhancer- binding factor 1
- ROR ⁇ t orphan hormone receptor ROR ⁇ t
- the inventors were able to obtain mature CD4 T cells at the expense of CD8 T cells.
- the OP9 stromal cells do not express human leukocyte antigen (HLA) class I or class II, it is possible that human thymocytes, however, can provide sufficient class I and class II HLA contacts for maturing DP T cells and induce positive selection (Fig. Sl B) (46, 47).
- HLA human leukocyte antigen
- Fig. Sl B human thymocytes
- the lineage commitment to CD4 T cells can be explained by the kinetic signaling model, which proposes that DP T cell adopts a CD4 T cell path when receive a positive selecting TCR signal followed by a persistent TCR stimulation; if the TCR signal ceases, the DP cell adopts the CD8 T cell path (20, 24).
- the inventors provide the IL-7 deprived differentiating T cell precursors with a prolonged TCR signal via anti-CD3/CD28 antibodies, which may account for the CD4 lineage choice.
- Human CD34 + cells and cell lines The adult bone marrow or mobilized peripheral blood CD34 + hematopoietic precursor/stem cells (HPC) from normal donors and cord blood CD34 + cells were purchased from AllCell Inc. (San Mateo, CA, USA) or Cambrex (Walkersville, MD).
- the mouse fetal stromal cells (OP9) were purchased from the American Type Culture Collection (ATCC, Manassas, VA).
- the engineered LmDLl and LmDLl-FL7 cell lines were generated by transducing cells with lentiviral vectors encoding mouse Delta like 1 (DLl), and DLl, human Flt3L, plus human IL-7, respectively.
- stromal cells were maintained in ⁇ -MEM (Invitrogen/Gibco BRL, Grand Island, NY) supplemented with 20% fetal bovine serum (FBS, Invitrogen/Gibco BRL) and 1% Penicillin-Streptomycin (Mediatech Inc., Manassas, VA).
- FBS fetal bovine serum
- Penicillin-Streptomycin Mediatech Inc., Manassas, VA
- IL-7 cytokine secretion was measured by using Human IL-7 ELISA kit.
- Cell free supernatants were obtained from LmDLl and LmDLFL7 cells cultured for 48 hrs (80-90% confluent), in a 12 well plate containing 1 ml of media (Ray Biotech, Inc). The samples were read on model 680 microplate reader (Bio-Rad).
- the surface expression of DLl and Flt3L was analyzed by flow cytometry with Alexa Fluor 647-conjugated anti-DLl Ab (Biolegend) and purified anti-Flt3L Ab (Abeam Inc. Cambridge, MA) conjugated with zenon-alexa 488 according to manufacturer's instructions (Invitrogen).
- LmDLl stromal cell - CD34 + HPC coculture LmDLl stromal cell - CD34 + HPC coculture.
- the CD34 + HPC were seeded into 24-well-plate at 1x10 5 cells/well containing a confluent monolayer of LmDLl or LmDLl-FL7 cells.
- the cocultures were maintained in complete medium starting from day 1 , consisting of ⁇ -MEM with 20% FBS and 1% Penicillin-Streptomycin, supplemented with 5 ng/ml IL-7 (PeproTech, Inc. Rocky Hill, NJ) and 5 ng/ml Flt3L (PeproTech, Inc.) as indicated.
- the cocultures were replenished with new media every 2-3 days.
- the cells in suspension were transferred to a new confluent stromal monolayer once the monolayer began to differentiate or when developing cells reach 80-90% confluent.
- the cells were transferred by vigorous pipetting, followed by filtering through a 70 ⁇ m filter (BD/Falcon, BD Biosciences, Sparks, MD) and centrifugation at 250 g, at room temperature for 10 min.
- the cell pellet was transferred to a fresh confluent monolayer.
- the cells were harvested at the indicated time points during the T cell development for analysis.
- the antibodies used for surface staining included CD4 (clone RPA-T4, PE, FITC, PE-Cy7 and Pacific Blue), CD8 (clone RPA-T8 PE, FITC, PE- Cy7 and Pacific Blue), CD3 (clone SK7, PE-Cy7), TCR ⁇ (clone T10B9.1A-31, FITC) were from BD biosciences, San Jose, CA. Cells were first washed with PBS plus 2% FBS and blocked with mouse and human serum at 4°C for 30 min. For each antibody staining, cells were incubated with antibodies per manufacturer's instructions. For each fluorochrome-labeled Ab used, appropriate isotype control was included.
- T cell stimulation by anti-CD3/CD28 beads To stimulate na ⁇ ve T cells, a protocol for long term stimulation was followed using anti-CD3/CD28 beads (Dynal/Invitrogen, San Diego, CA) per manufacturer's instructions. The cells and the beads were mixed and plated into a 96 well plate at 37 0 C for 2-3 days in X-vivo 20 (BioWhittaker, Cambrex, Walkersville, MD) media, on day 3 12.5U of IL-2, 5 ng/ml of IL-7 and 20 ng/ml of IL-15 were added and the cells were cultured for additional 11-12 days.
- X-vivo 20 BioWhittaker, Cambrex, Walkersville, MD
- CD4 clone RPA-T4, PE, FITC, PE-Cy7 and Pacific Blue
- CD8 clone RPA-T8 PE, FITC, PE-Cy7 and Pacific Blue
- CD3 clone SK7, PE-Cy7
- TCR ⁇ clone T10B9.1A-31, FITC
- CDIa clone HI149, APC
- CD28 clone CD28.2, APC
- Intracellular staining was done using anti-Ki67 (clone B56, FITC), and isotype IgGiK from BD biosciences.
- Intracellular staining was done using anti-Ki67 FITC, and isotype IgGiK (BD Biosciences). Intracellular staining was performed using BD cytof ⁇ x/cytoperm kit, according to the manufacturer's protocol. Effector function analysis of in vitro generated CD4 + T cells.
- the CD3/CD28 expanded CD4 T cells were stimulated with PMA and Ionomycin (Sigma- Aldrich, St. Louis, MO), and analyzed for the release of IFN- ⁇ , IL-4 and IL-17.
- the cells were incubated with 25 ng/ml PMA and 1 ⁇ g/ml Ionomycin for one hour followed by addition of 6 ⁇ g/ml monensin (Sigma-Aldrich) to inhibit Golgi-mediated cytokine secretion.
- CD4 clone RPA-T4, Pacific blue, CD8 (clone SKl, APC- Cy7), CD3 (clone SK7 PE-Cy7), CD25 (clone M-A251, PE) and intracellular stained for IFN- ⁇ - (clone 25723.11, FITC), IL-4- (clone MP425D2, APC, FOXP3 (clone PCHlOl, Alexa 647) were from BD Biosciences, IL-17 (clone 64CAP17, PE) was from e-Biosciences. The data were collected by flow cytometry using BD FACSAria and analyzed using Flowjo.
- V ⁇ repertoire analysis of in vitro derived CD4 + T cells The V ⁇ repertoire of in vitro developed T lymphocytes was analyzed by using IOTest® Beta Mark TCR V ⁇ Repertoire Kit (Beckman Coulter, Fullerton, CA). Staining for 24 V ⁇ families was performed according to manufacturer's protocol.
- Antibodies used were , HLA Class I (clone TU149, PE) from Clatag, HLA DR DQ DP (clone TU39, FITC) from BD biosciences. RT-PCR
- IL-7 receptor signals inhibit expression of transcription factors TCF-I, LEF-I, and RORgammat: impact on thymocyte development. The Journal of experimental medicine 200:797-803.
- IL-7 promotes the survival and maturation but not differentiation of human post-thymic CD4+ T cells. Eur J Immunol 28:3057-3065.
- IL-7R alpha gene expression is inversely correlated with cell cycle progression in IL-7-stimulated T lymphocytes. J Immunol 176:6702-6708.
- Thymocytes positively select thymocytes in human system. Human immunology 54:15- 20
- the present invention in various embodiments, includes providing devices and processes in the absence of items not depicted and/or described herein or in various embodiments hereof, including in the absence of such items as may have been used in previous devices or processes, e.g., for improving performance, achieving ease and/or reducing cost of implementation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009801448281A CN102216446A (en) | 2008-09-11 | 2009-09-11 | System and method for producing T cells |
JP2011527010A JP2012508561A (en) | 2008-09-11 | 2009-09-11 | System and method for producing T cells |
EP09813717A EP2321407A4 (en) | 2008-09-11 | 2009-09-11 | System and method for producing t cells |
US13/062,570 US20110236363A1 (en) | 2008-09-11 | 2009-09-11 | System and method for producing t cells |
AU2009291595A AU2009291595A1 (en) | 2008-09-11 | 2009-09-11 | System and method for producing T cells |
CA2736851A CA2736851A1 (en) | 2008-09-11 | 2009-09-11 | System and method for producing t cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9624008P | 2008-09-11 | 2008-09-11 | |
US61/096,240 | 2008-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010030947A1 true WO2010030947A1 (en) | 2010-03-18 |
Family
ID=42005508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2009/056739 WO2010030947A1 (en) | 2008-09-11 | 2009-09-11 | System and method for producing t cells |
Country Status (7)
Country | Link |
---|---|
US (1) | US20110236363A1 (en) |
EP (1) | EP2321407A4 (en) |
JP (1) | JP2012508561A (en) |
CN (1) | CN102216446A (en) |
AU (1) | AU2009291595A1 (en) |
CA (1) | CA2736851A1 (en) |
WO (1) | WO2010030947A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2960882A1 (en) * | 2010-06-04 | 2011-12-09 | Hospices Civils Lyon | Use of mononucleated cells activated in presence of mesenchymal cells to obtain interleukin-17 producing cells, and to treat infection, cancer or autoimmune diseases such as rheumatoid arthritis, psoriasis and multiple sclerosis |
US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
EP3415617A1 (en) * | 2017-06-16 | 2018-12-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | A method and a device for increasing ex vivo expansion of t cells by using adhesive nanostructured surfaces and costimulatory signals |
US10189777B2 (en) | 2014-05-05 | 2019-01-29 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease |
US10421751B2 (en) | 2015-05-05 | 2019-09-24 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
US10532088B2 (en) | 2014-02-27 | 2020-01-14 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
US10611740B2 (en) | 2015-06-11 | 2020-04-07 | Lycera Corporation | Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
KR101749195B1 (en) | 2011-12-12 | 2017-06-20 | 셀 메디카 리미티드 | Process of expanding t cells |
HRP20221303T1 (en) | 2012-02-09 | 2022-12-23 | Baylor College Of Medicine | Pepmixes to generate multiviral ctls with broad specificity |
AU2014265487B2 (en) | 2013-05-14 | 2020-10-22 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (CAR) T-cells |
AU2014268364A1 (en) | 2013-05-24 | 2015-12-10 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
EP3060059A4 (en) * | 2013-10-25 | 2017-11-01 | Board of Regents, The University of Texas System | Polyclonal gamma delta t cells for immunotherapy |
EP3105335B1 (en) | 2014-02-14 | 2019-10-02 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors and methods of making |
CN104789529A (en) * | 2015-04-28 | 2015-07-22 | 济南劲牛生物科技有限公司 | Method for promoting mouse bone marrow hematopoietic stem cell in vitro clone formation and differentiation ability |
US11680244B2 (en) | 2015-05-20 | 2023-06-20 | The Regents Of The University Of California | Method for generating human dendritic cells for immunotherapy |
IL298359A (en) | 2015-09-18 | 2023-01-01 | Baylor College Medicine | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy |
TW202344686A (en) * | 2015-10-30 | 2023-11-16 | 美國加利福尼亞大學董事會 | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
JP7215994B2 (en) | 2016-09-06 | 2023-01-31 | ザ チルドレンズ メディカル センター コーポレーション | Immune cells derived from induced pluripotent stem cells |
AR120348A1 (en) * | 2019-11-01 | 2022-02-09 | Univ Kyoto | METHOD FOR PRODUCING T CELLS |
AU2021211713A1 (en) | 2020-01-23 | 2022-08-25 | The Children's Medical Center Corporation | Stroma-free T cell differentiation from human pluripotent stem cells |
CN112795539B (en) * | 2020-12-31 | 2023-04-28 | 中山大学 | Method for analyzing stem cell cytokines by cell flow |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020127208A1 (en) * | 2000-08-31 | 2002-09-12 | Waller Edmund K. | Method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease |
US20030166278A1 (en) * | 1999-08-19 | 2003-09-04 | Gimble Jeffrey Martin | Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof |
US20060068494A1 (en) * | 2004-09-30 | 2006-03-30 | Claude Perreault | WNT4 in supporting lymphopoiesis |
US20080206210A1 (en) * | 2004-06-03 | 2008-08-28 | Naomi Taylor | Drugs for the Prevention or Treatment of Immunodeficiencies, Autoimmune Diseases or for the Induction of Immune Tolerance |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7575925B2 (en) * | 2002-12-10 | 2009-08-18 | Sunnybrook Health Sciences Centre | Cell preparations comprising cells of the T cell lineage and methods of making and using them |
AU2007347364A1 (en) * | 2007-02-21 | 2008-08-28 | Adelaide Research & Innovation Pty Ltd | Method for obtaining TREG-cells |
-
2009
- 2009-09-11 CN CN2009801448281A patent/CN102216446A/en active Pending
- 2009-09-11 CA CA2736851A patent/CA2736851A1/en not_active Abandoned
- 2009-09-11 EP EP09813717A patent/EP2321407A4/en not_active Withdrawn
- 2009-09-11 US US13/062,570 patent/US20110236363A1/en not_active Abandoned
- 2009-09-11 AU AU2009291595A patent/AU2009291595A1/en not_active Abandoned
- 2009-09-11 WO PCT/US2009/056739 patent/WO2010030947A1/en active Application Filing
- 2009-09-11 JP JP2011527010A patent/JP2012508561A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030166278A1 (en) * | 1999-08-19 | 2003-09-04 | Gimble Jeffrey Martin | Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof |
US20020127208A1 (en) * | 2000-08-31 | 2002-09-12 | Waller Edmund K. | Method of transplantation using chemotherapy-treated allogeneic cells that enhance immune responses without graft versus host disease |
US20080206210A1 (en) * | 2004-06-03 | 2008-08-28 | Naomi Taylor | Drugs for the Prevention or Treatment of Immunodeficiencies, Autoimmune Diseases or for the Induction of Immune Tolerance |
US20060068494A1 (en) * | 2004-09-30 | 2006-03-30 | Claude Perreault | WNT4 in supporting lymphopoiesis |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2960882A1 (en) * | 2010-06-04 | 2011-12-09 | Hospices Civils Lyon | Use of mononucleated cells activated in presence of mesenchymal cells to obtain interleukin-17 producing cells, and to treat infection, cancer or autoimmune diseases such as rheumatoid arthritis, psoriasis and multiple sclerosis |
US10532088B2 (en) | 2014-02-27 | 2020-01-14 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
US9896441B2 (en) | 2014-05-05 | 2018-02-20 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
US10189777B2 (en) | 2014-05-05 | 2019-01-29 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease |
US10364237B2 (en) | 2014-05-05 | 2019-07-30 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
US10442798B2 (en) | 2014-05-05 | 2019-10-15 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
US10421751B2 (en) | 2015-05-05 | 2019-09-24 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
US10611740B2 (en) | 2015-06-11 | 2020-04-07 | Lycera Corporation | Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
US11059796B2 (en) | 2015-06-11 | 2021-07-13 | The Regents Of The University Of Michigan | Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
EP3415617A1 (en) * | 2017-06-16 | 2018-12-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | A method and a device for increasing ex vivo expansion of t cells by using adhesive nanostructured surfaces and costimulatory signals |
Also Published As
Publication number | Publication date |
---|---|
CN102216446A (en) | 2011-10-12 |
AU2009291595A2 (en) | 2011-08-04 |
EP2321407A4 (en) | 2012-07-18 |
US20110236363A1 (en) | 2011-09-29 |
EP2321407A1 (en) | 2011-05-18 |
AU2009291595A1 (en) | 2010-03-18 |
JP2012508561A (en) | 2012-04-12 |
CA2736851A1 (en) | 2010-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20110236363A1 (en) | System and method for producing t cells | |
AU2018254442B2 (en) | Antigen-specific immune effector cells | |
KR102575976B1 (en) | Proliferation method of natural killer cells | |
JP7092281B2 (en) | Methods and kits for generating mimic innate immune cells from pluripotent stem cells | |
JP7136454B2 (en) | Method for producing CD8α+β+ cytotoxic T cells | |
US8785189B2 (en) | Method of forming dendritic cells from embryonic stem cells | |
WO2017100403A1 (en) | Human t cell derived from t cell-derived induced pluripotent stem cell and methods of making and using | |
CA3001507C (en) | Cxcr6-transduced t cells for targeted tumor therapy | |
WO2017194924A1 (en) | Methods of sorting and culturing t cells | |
KR20220047376A (en) | How to produce T cells | |
CN114402065A (en) | Low density cell culture | |
US20230149466A1 (en) | Immunotherapeutic methods and compositions for targeting cancer fibroblasts | |
KR101232128B1 (en) | Method for Preparing Mature Dedritic Cell with Excellent Immune Activity | |
WO2012065156A2 (en) | Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells | |
JP7014820B2 (en) | Method for producing and using embryonic mesenchymal primordial cells | |
Naito et al. | Mature dendritic cells generated from patient-derived peripheral blood monocytes in one-step culture using streptococcal preparation OK-432 exert an enhanced antigen-presenting capacity | |
JP2024525910A (en) | Methods for generating populations of immune cells from pluripotent stem cells | |
Du | Co-Expansion of Gamma Delta T Cells and Cytokine Induced Killer Cells for Adoptive Immune Cell Therapy | |
Lin | In vitro generation of hematopoietic progenitors and functional T cells from pluripotent stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980144828.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09813717 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2736851 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2011527010 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 460/MUMNP/2011 Country of ref document: IN Ref document number: 2009813717 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009291595 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2009291595 Country of ref document: AU Date of ref document: 20090911 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13062570 Country of ref document: US |